SCHEMBL23684547

SCHEMBL23684547

O=C(O)c1cccc(CC2CCOCC2)c1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GRIK1 P39086 2/20 0.51
▸ FOLH1 Q04609 1/20 0.50
▸ PPM1D O15297 2/20 0.49
▸ KMO O15229 1/20 0.47
▸ MRGPRX4 Q96LA9 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ HIF1A Q16665 1/20 0.46
▸ OPRM1 P35372 1/20 0.45
▸ OPRD1 P41143 1/20 0.45
▸ OPRK1 P41145 1/20 0.45
▸ KCNH2 Q12809 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ NPSR1 Q6W5P4 1/20 0.44
▸ GAA P10253 1/20 0.43
▸ EPHX1 P07099 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9005566 0.84 PPM1D (0.64) GRIK1FOLH1PPM1DKMOMRGPRX4
SCHEMBL9005670 0.84 PPM1D (0.64) GRIK1FOLH1PPM1DKMOMRGPRX4
SCHEMBL17982795 0.82 GRIK1 (0.46) GRIK1FOLH1PPM1DMRGPRX4CYP2D6
SCHEMBL1633286 0.82 GBA1 (0.60) GRIK1FOLH1PPM1DMRGPRX4CYP2D6
SCHEMBL29668711 0.80 FOLH1 (0.51) GRIK1FOLH1PPM1DMRGPRX4CYP2D6
SCHEMBL23684186 0.80 SLC7A5 (0.51) PPM1DMRGPRX4OPRM1OPRD1OPRK1
SCHEMBL3150745 0.80 FOLH1 (0.54) GRIK1FOLH1MRGPRX4CYP2D6CYP2C9
SCHEMBL12725438 0.79 MEN1 (0.50) GRIK1FOLH1CYP2D6CYP2C9HIF1A
SCHEMBL15830232 0.78 PRMT5 (0.51) FOLH1PPM1DKMOMRGPRX4HIF1A
SCHEMBL5732970 0.77 LMNA (0.38) MRGPRX4OPRM1OPRD1OPRK1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11986471-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2024-05-21 — — US disclosed
US-20230060499-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20230060499-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-11077101-B1 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2021-08-03 — — US disclosed
US-11077101-B1 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2021-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11986471-B2 Compounds and methods of use XDH, F12, LPXN GRIK1 2217/4885FOLH1 3306/4885PPM1D 2026/4885
US-11077101-B1 Compounds and methods of use XDH, F12, LPXN GRIK1 2217/4885FOLH1 3306/4885PPM1D 2026/4885
US-20230060499-A1 COMPOUNDS AND METHODS OF USE XDH, F12, LPXN GRIK1 2217/4885FOLH1 3306/4885PPM1D 2026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback